Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US7125870B2 · kind B2 · utility
1Cited by
5References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2003 |
| Grant date | Oct 24, 2006 |
| Priority date | — |
| Expiry date | Sep 24, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present application describes novel isoxazoline of formula I or II:or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.